Trump-era tariffs are noted to benefit certain AI stocks, while Ultragenyx and Mereo are involved in the ORBIT study.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Trump-era tariffs are noted to benefit certain AI stocks, while Ultragenyx and Mereo are involved in the ORBIT study.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
Related events
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Trump tariffs and onshoring benefit AI stocks, leading to automation and robotics support agreements involving Amazon and Richtech Robotics.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
Coverage
Newest first; wire copies grouped- Insider MonkeyMereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 Mereo BioPharma Group plc (NASDAQ:MREO) is one of the Best 52-Week Low Penny Stocks to Buy Now. On July 9, Mer